Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Two Captopril Formulations in Healthy Adults
NCT04878315Phase 1Withdrawn
- Sponsor
- GSK
- Start
- Feb 2022
- Primary completion
- Mar 2022
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of captopril in hypertension (HTN) (3 arms), sponsored by GSK. Primary endpoints: Maximum observed concentration up to 3 weeks, Area under the concentration-time curve from administration to last quantifiable concentration up to 3 weeks and 1 more. Planned start Feb 2022; status: withdrawn.
02
Drugs
captopril
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT04878315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04878315.